Racial Disparity of Epidermal Growth Factor Receptor Expression in Prostate Cancer
| Autor: | Jaya M. Satagopan, Peng Lee, Herman Yee, Brian Shuch, Maryann Mikhail, Caroline Chang, Samir S. Taneja, Iman Osman, Carlos Cordon-Cardo |
|---|---|
| Rok vydání: | 2004 |
| Předmět: |
Adult
Male Oncology Cancer Research medicine.medical_specialty Racial disparity White People Cohort Studies Prostate cancer Growth factor receptor Internal medicine Biomarkers Tumor medicine Humans Epidermal growth factor receptor Stage (cooking) Aged Neoplasm Staging Probability Retrospective Studies EGFR inhibitors Prostatectomy biology business.industry Biopsy Needle Prostatic Neoplasms Middle Aged Prognosis medicine.disease Immunohistochemistry Survival Analysis Black or African American ErbB Receptors Gene Expression Regulation Neoplastic Endocrinology Multivariate Analysis Cohort biology.protein Signal transduction business |
| Zdroj: | Journal of Clinical Oncology. 22:4725-4729 |
| ISSN: | 1527-7755 0732-183X |
| DOI: | 10.1200/jco.2004.06.134 |
| Popis: | Purpose The epidermal growth factor receptor (EGFR) plays a critical role in prostate cancer (PC) signal transduction and is the target of a novel class of anticancer agents. Despite recent reports of interethnic variation in response to EGFR inhibitors, limited information exists regarding differences in expression of EGFR in PC patients. This has therapeutic relevance because a better understanding of the molecular basis underlying the ethnic variability will help in the design of individualized treatment regimens using EGFR inhibitors. Patients and Methods We investigated EGFR expression in a well-characterized cohort of PC patients to determine the association between EGFR expression and race. Tumor tissues from 202 radical prostatectomies performed between 1990 and 2000 at the Veterans Administration Medical Center (New York, NY) were studied (142 African Americans, 60 whites; median age, 67 years; stage T2, n = 130; stage ≥ T3, n = 72; Gleason score < 7, n = 110; Gleason score ≥ 7, n = 92). Membrane-specific EGFR expression was evaluated immunohistochemically. Results EGFR overexpression, defined as complete membrane staining in more than 10% of tumor cells, was observed in 75 of 202 patients (37%). There was a significant association between EGFR overexpression and African American race (P = .0006), higher pretreatment prostate-specific antigen (PSA; P = .02), and stage (P = .02), but not Gleason score (P = .33). The association between African American race and EGFR overexpression remained significant in a multivariate model after controlling for grade, stage, and pretreatment PSA simultaneously (P = .003). Conclusion Our data demonstrate that race contributes significantly to variability of EGFR expression in prostate cancer. Racial background may have an impact on the design of clinical trials to test the efficacy of anti-EGFR agents. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|